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Background
Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared 
with uncoated stents. Data are limited regarding the safety and efficacy of such 
stents in primary percutaneous coronary intervention (PCI) for acute myocardial 
infarction with ST-segment elevation.
Methods
We performed a single-blind, multicenter, prospectively randomized trial to com-
pare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocar-
dial infarction with ST-segment elevation. The trial included 712 patients at 48 
medical centers. The primary end point was target-vessel failure at 1 year after the 
procedure, defined as target-vessel–related death, recurrent myocardial infarction, 
or target-vessel revascularization. A follow-up angiographic substudy was performed 
at 8 months among 174 patients from selected centers.
Results
The rate of the primary end point was significantly lower in the sirolimus-stent 
group than in the uncoated-stent group (7.3% vs. 14.3%, P = 0.004). This reduction 
was driven by a decrease in the rate of target-vessel revascularization (5.6% and 
13.4%, respectively; P<0.001). There was no significant difference between the two 
groups in the rate of death (2.3% and 2.2%, respectively; P = 1.00), reinfarction (1.1% 
and 1.4%, respectively; P = 1.00), or stent thrombosis (3.4% and 3.6%, respectively; 
P = 1.00). The degree of neointimal proliferation, as assessed by the mean (±SD) 
in-stent late luminal loss, was significantly lower in the sirolimus-stent group 
(0.14±0.49 mm, vs. 0.83±0.52 mm in the uncoated stent group; P<0.001).
Conclusions
Among selected patients with acute myocardial infarction, the use of sirolimus-elut-
ing stents significantly reduced the rate of target-vessel revascularization at 1 year. 
(ClinicalTrials.gov number, NCT00232830.)
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T he use of sirolimus-eluting coro-nary-artery stents significantly reduces the incidence of restenosis after percutaneous 
coronary intervention (PCI), as compared with 
the use of uncoated stents.1-3 However, most ran-
domized trials evaluating sirolimus-eluting stents 
have excluded patients with acute myocardial in-
farction with ST-segment elevation. Small series 
of patients with acute myocardial infarction have 
shown that the implantation of a sirolimus-elut-
ing stent is associated with a low rate of resteno-
sis.4,5 In the Single High-Dose Bolus Tirofiban and 
Sirolimus-Eluting Stent vs. Abciximab and Bare-
Metal Stent in Myocardial Infarction (STRATEGY) 
trial, the use of sirolimus-eluting stents reduced 
cardiovascular events, as compared with the use 
of uncoated stents, in a small group of patients 
undergoing primary PCI. However, the design of 
the trial specified the use of different glycopro-
tein IIb/IIIa inhibitors in each of the two groups 
to mitigate the greater cost of the drug-eluting 
stents, which raised the possibility that the ben-
efit was influenced by the specific antiplatelet 
regimen.6
We therefore designed a prospective, random-
ized, multicenter trial comparing the effective-
ness of sirolimus-eluting stents with that of un-
coated stents in primary PCI for acute myocardial 
infarction with ST-segment elevation.
Methods
Enrollment and Assignment of Patients
We enrolled patients at 48 centers in 15 countries 
to participate in the Trial to Assess the Use of the 
Cypher Stent in Acute Myocardial Infarction Treat-
ed with Balloon Angioplasty (TYPHOON). The 
study protocol was approved by the ethics com-
mittee at each participating institution and was 
conducted according to the principles of the Dec-
laration of Helsinki. All patients gave written in-
formed consent before enrollment. The study was 
conducted from October 2003 to October 2005.
Patients were eligible for the trial if their symp-
toms began less than 12 hours before catheter-
ization and if the electrocardiogram showed ST-
segment elevation (at least 1 mm in two or more 
standard leads or at least 2 mm in two or more 
contiguous precordial leads). Clinical criteria for 
exclusion included the administration of fibrino-
lytic agents for the index infarction, overt acute 
heart failure, a previously documented left ven-
tricular ejection fraction of less than 30%, previ-
ous myocardial infarction, and an estimated life 
expectancy of less than 12 months.
Diagnostic Angiography and Primary 
Intervention
Patients were premedicated with aspirin (at least 
100 mg) and unfractionated heparin (5000 to 
10,000 IU). A loading dose of 300 mg of clopido-
grel was administered either before or immedi-
ately after PCI. Coronary angiography was per-
formed through the femoral or radial artery with 
the use of standard techniques.
Selection and Randomization
The trial protocol required visualization of the 
culprit lesion before randomization, in order to 
determine whether the angiographic criteria for 
inclusion or exclusion were met. Randomization 
was therefore performed either immediately after 
coronary angiography if the infarct-related vessel 
was spontaneously patent or after reestablish-
ing coronary-artery blood flow by the placement 
of a guidewire or by balloon angioplasty.
Criteria for angiographic exclusion included 
previous PCI of the infarct-related vessel, exces-
sive tortuosity or calcification, ostial or multiple 
lesions, massive thrombus in the infarct-related 
artery, bifurcation or left main coronary-artery 
disease, and severe multivessel disease requiring 
surgical revascularization. Patients were finally 
included and randomly assigned to a treatment 
group if the target lesion had a maximum length 
of 30 mm and was located in a native coronary 
artery with a reference-vessel diameter of 2.25 
mm to 3.50 mm.
Random assignments to the treatment groups 
were generated in blocks of four or six and were 
distributed in sealed envelopes to each partici-
pating center. Patients were randomly assigned 
to the groups in a 1:1 ratio. Patients received ei-
ther a sirolimus-eluting stent (Cypher or Cypher 
Select, Cordis, Johnson & Johnson) or any com-
mercially available uncoated stent. Patients, but 
not investigators, were unaware of the treatment 
assignment.
Stent Implantation
Direct implantation of a stent without previous 
balloon angioplasty was allowed if the culprit le-
sion was adequately visualized either spontane-
ously or after guidewire placement. In the case of 
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insufficient stent expansion, the stent was dilat-
ed after placement with another angioplasty bal-
loon that was shorter than the total length of the 
stent. Oversizing and additional high-pressure 
dilation after the initial procedure were not rec-
ommended. If more than one stent was implant-
ed, the same type of stent (sirolimus-eluting or 
uncoated) was recommended. Intervention in non-
infarct-related arteries during the initial proce-
dure was discouraged.
Heparin was administered throughout the pro-
cedure in order to maintain an activated clotting 
time of 250 seconds or longer. Administration of 
platelet glycoprotein IIb/IIIa–receptor inhibitors 
was left to the investigator’s discretion.
Follow-up
Clinical follow-up was performed at 30 days and 
at 6 and 12 months after the procedure. Combined 
antiplatelet therapy included daily administra-
tion of aspirin (100 mg) and either clopidogrel 
(75 mg) or ticlopidine (250 mg). Dual antiplatelet 
therapy was recommended for at least 6 months, 
and aspirin therapy was recommended indefi-
nitely. Noninvasive testing to assess for evidence 
of ischemia was recommended before repeated 
revascularization. Patients were unaware of their 
treatment assignments throughout the follow-up 
period.
Angiographic follow-up at 8 months was planned 
for 200 patients at 12 centers. In these selected 
centers, consecutive patients were enrolled in the 
angiographic substudy until the total number of 
patients reached 210.
Quantitative Coronary Angiography
Technicians at an independent angiographic core 
laboratory (BioImaging, Leiden, the Netherlands), 
who were unaware of treatment assignment, an-
alyzed all angiographic images with the use of 
edge-detection techniques.7 Binary restenosis was 
defined as stenosis of more than 50% of the lu-
minal diameter. Late luminal loss was calculated 
as the difference between the minimum luminal 
diameter immediately after the procedure and at 
8 months. Flow in the infarct-related vessel was 
graded according to the Thrombolysis in Myo-
cardial Infarction (TIMI) trial classification.8
Primary and Secondary End Points
The primary end point of the study was target-
vessel failure, defined as the composite of target-
vessel revascularization, recurrent infarction, or 
target-vessel–related death at 1 year. The clinical 
events committee reviewed and adjudicated all 
serious clinical events, including stent throm-
bosis.
Target-vessel revascularization was defined as 
repeated PCI or bypass grafting of the target ves-
sel, driven by clinical symptoms of myocardial 
ischemia, a positive stress test, electrocardiograph-
ic evidence of ischemic changes at rest attribut-
able to the target vessel, or an in-lesion stenosis 
of more than 70% of the reference luminal diam-
eter by visual estimate.
Recurrent infarction was defined as the recur-
rence of clinical symptoms or the occurrence of 
electrocardiographic changes accompanied by a 
new elevation in levels of creatine kinase, creatine 
kinase MB enzyme, or both. The level of creatine 
kinase required for the diagnosis of reinfarction 
depended on the interval from the index infarc-
tion: the creatine kinase level had to be at least 
1.5 times the previous value if new symptoms ap-
peared within 48 hours and at least 3 times the 
upper limit of normal if new symptoms appeared 
after 48 hours.
Death from cardiac causes included death from 
acute myocardial infarction, cardiac perforation, 
or pericardial tamponade; an arrhythmia or con-
duction abnormality; complications of the inter-
ventional procedure at baseline; stroke (including 
bleeding) within 30 days after the procedure or in 
connection with the procedure; and all deaths that 
could not be clearly attributed to a noncardiac 
cause.
The secondary end points of the trial includ-
ed the rate of successful treatment of the lesion, 
defined by residual stenosis of less than 50% of 
the reference luminal diameter on quantitative 
coronary analysis and a TIMI f low grade of 
3, and in-stent late luminal loss on quantitative 
coronary analysis at 8 months.
Definition of Stent Thrombosis
Stent thrombosis was classified as acute if it oc-
curred within 24 hours after the index procedure, 
subacute if it occurred between 1 and 30 days, 
and late if it occurred after 30 days. Acute and 
subacute stent thrombosis were defined as an-
giographic proof of vessel occlusion, any recur-
rent Q-wave myocardial infarction in the territory 
of the stented vessel, or any death from cardiac 
causes. Late stent thrombosis was defined as any 
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recurrent myocardial infarction with angiograph-
ic proof of vessel occlusion.
Study Design and Administration
Our study was proposed to the industry sponsor 
by four of the academic investigators: Drs. Hen-
ry, Spaulding, Teiger, and Slama. The same inves-
tigators wrote the final version of the protocol 
in collaboration with the industry sponsor, and 
the steering committee approved the design. Dr. 
Spaulding designed the statistical-analysis plan 
in collaboration with the sponsor.
Data were collected with the use of an elec-
tronic case-report form through a secured In-
ternet-based Web site. A clinical research or-
ganization (Hesperion, Allschwil, Switzerland) 
performed all study monitoring, data manage-
ment, and statistical analysis. The industry spon-
sor had no direct role in the collection or analysis 
of data. The steering committee had unrestrict-
ed access to the data and made all decisions 
about publication independently of the sponsor. 
Dr. Spaulding assumes overall responsibility for 
the integrity of the data, the accuracy of the data 
analyses, and the completeness of the material 
reported.
715 Patients enrolled
356 Assigned to receive
sirolimus-eluting stents
359 Assigned to receive
uncoated stents
2 Withdrew informed consent
after stenting
1 Withdrew informed consent
after stenting
355 Participated in follow-up
104 Enrolled in angiographic
follow-up study
90 Participated in 8-mo
angiographic study; 87
included in analysis
106 Enrolled in angiographic
follow-up study
84 Participated in 8-mo
angiographic study; 83
included in analysis
357 Participated in follow-up
355 Underwent analysis in 1-yr
follow-up study
357 Underwent analysis in 1-yr
follow-up study
Figure 1. Enrollment and Outcomes. 
A subgroup of 210 patients were enrolled in the angiographic follow-up study; of these patients, 174 actually 
returned for follow-up angiography and 170 had qualifying angiograms.
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Statistical Analysis
The planned enrollment of 700 patients provided 
a statistical power of 80% to detect a 47% reduc-
tion in the rate of the primary end point at 1 year 
(from 17% in the uncoated-stent group to 9% in 
the sirolimus-stent group) with a 5% rate of false 
positive results in a two-sided test. The estimated 
enrollment for the angiographic substudy was 
based on an assumed in-stent late luminal loss of 
0.43 mm in the sirolimus-stent group and 0.76 mm 
in the uncoated-stent group at 8 months, with an 
SD of 0.7 mm for both groups.2,9 After correction 
for loss to follow-up, we estimated that the enroll-
ment of 200 patients provided 80% power with 
a false positive rate of 5% in a two-sided test.
All analyses were based on the intention to 
treat. The differences between the treatment 
groups were evaluated by analysis of variance or 
Wilcoxon rank-sum scores for continuous vari-
ables, if appropriate. Fisher’s exact test was used 
for the analysis of categorical variables. The rate 
of survival free from target-vessel failure during 
the 1-year follow-up period was analyzed by the 
Kaplan–Meier method, and the difference in sur-
vival curves between the groups was assessed 
with the log-rank test. To test whether initial dif-
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Sirolimus-Eluting 
Stent
(N = 355)
Uncoated Stent 
(N = 357) P Value
Age — yr 58.0±11.8 60.5±12.4 0.008
Male sex — no. (%) 279 (78.6) 279 (78.2) 0.93
Diabetes — no. (%) 55 (15.5) 61 (17.1) 0.61
Hypertension — no. (%) 137 (38.6) 152 (42.6) 0.29
Hyperlipidemia — no. (%) 144 (40.6) 156 (43.7) 0.40
Current smoker — no. (%) 170 (47.9) 186 (52.1) 0.29
Previous PCI of noninfarct vessel — no. (%) 9 (2.5) 21 (5.9) 0.04
Previous stroke — no. (%) 7 (2.0) 7 (2.0) 1.00
Time from onset of chest pain to admission — min 0.66
Median 234 228
Interquartile range 108–300 120–288
Time from admission to angiography — min 0.78
Median 38 37
Interquartile range 10–45 10–45
Time from hospitalization to angioplasty — min 0.97
Median 60 60
Interquartile range 30–71 30–73
Systolic blood pressure at admission — mm Hg 131±23 131±24 0.95
Infarct-related vessel — no. (%) 0.006
Left anterior descending coronary artery 177 (49.9) 146 (40.9) 0.02
Right coronary artery 130 (36.6) 157 (44.0) 0.06
Left circumflex coronary artery 48 (13.5) 54 (15.1) 0.59
Extent of coronary disease — no. (%) 0.04
1 vessel 198 (55.8) 178 (49.9) 0.12
2 vessels 118 (33.2) 121 (33.9) 0.87
3 vessels 39 (11.0) 58 (16.2) 0.05
Ejection fraction — % 52±11 53±12 0.65
* Plus–minus values are means ±SD. 
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Table 2. Procedural Results and Use of Medication during the Trial.*
Variable
Sirolimus-Eluting 
Stent 
(N = 355)
Uncoated Stent
(N = 357) P Value
Characteristics of stent implantation
No. of stents implanted 1.1±0.4 1.1±0.4 0.34
Total length of stent — mm 22.1±8.6 20.3±8.2 0.005
Maximal size of stent — mm 3.0±0.3 3.1±0.4 0.001
Maximal pressure — atm 13.8±2.7 13.2±2.5 0.002
Direct stenting — no. (%)
Attempted 165 (46.5) 169 (47.3) 0.82
Successful 162 (45.6) 165 (46.2) 0.88
Glycoprotein IIb/IIIa–receptor inhibitors — no. (%) 246 (69.3) 263 (73.7) 0.25
Abciximab 128 (36.1) 127 (35.6) 0.94
Other 118 (33.2) 136 (38.1) 0.18
Quantitative coronary analysis† 
Before procedure
No. evaluated 347 347
TIMI flow — no. (%)
Grade 0 or 1 230 (66.3) 234 (67.4) 0.81
Grade 2 70 (20.2) 53 (15.3) 0.11
Grade 3 47 (13.5) 60 (17.3) 0.21
Diameter of reference vessel — mm 2.78±0.50 2.84±0.61 0.36
Minimal luminal diameter — mm 0.20±0.33 0.19±0.35 0.82
Stenosis — % of luminal diameter 93.2±12.3 93.6±12.3 0.72
Immediately after procedure
No. evaluated 350 347
TIMI flow — no. (%)
Grade 0 or 1 2 (0.6) 2 (0.6) 1.00
Grade 2 11 (3.1) 14 (4.0) 0.55
Grade 3 337 (96.3) 331 (95.4) 0.58
Diameter of reference vessel — mm 2.84±0.49 2.90±0.52 0.09
Minimal luminal diameter — mm
In stent 2.49±0.39 2.58±0.44 0.01
In lesion 2.28±0.46 2.34±0.52 0.13
Stenosis — % of luminal diameter
In stent 13.5±7.6 12.4±8.4 0.05
In lesion 19.2±8.8 19.3±9.1 0.92
Acute gain — mm
In stent 2.42±0.47 2.41±0.53 0.92
In lesion 2.18±0.51 2.10±0.59 0.38
Successful treatment of lesion — no. (%)‡ 321 (95.5) 326 (95.9) 0.85
No. evaluated 336 340
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Table 2. (Continued.)
Variable
Sirolimus-Eluting 
Stent 
(N = 355)
Uncoated Stent
(N = 357) P Value
Medications used during the trial§
During hospital stay — no. (%)
No. evaluated 355 357
Aspirin 351 (98.9) 353 (98.9) 1.00
Clopidogrel 349 (98.3) 351 (98.3) 1.00
Ticlopidine 5 (1.4) 5 (1.4) 1.00
Beta-blockers 322 (90.7) 323 (90.5) 1.00
Statins 322 (90.7) 329 (92.2) 0.51
ACE inhibitors 262 (73.8) 275 (77.0) 0.34
Heparin 208 (58.6) 217 (60.8) 0.59
Follow-up at 1 mo — no. (%)
No. evaluated 340 346
Aspirin 334 (98.2) 336 (97.1) 0.45
Clopidogrel 334 (98.2) 337 (97.4) 0.60
Ticlopidine 3 (0.9) 2 (0.6) 0.68
Beta-blockers 303 (89.1) 311 (89.9) 0.80
Statins 318 (93.5) 322 (93.1) 0.88
ACE inhibitors 259 (76.2) 269 (77.7) 0.65
Follow-up at 6 mo — no. (%)
No. evaluated 334 339
Aspirin 312 (93.4) 318 (93.8) 0.88
Clopidogrel 253 (75.7) 249 (73.5) 0.54
Ticlopidine 1 (0.3) 1 (0.3) 1.00
Beta-blockers 294 (88.0) 290 (85.5) 0.36
Statins 311 (93.1) 316 (93.2) 1.00
ACE inhibitors 238 (71.3) 246 (72.6) 0.73
Follow-up at 1 yr — no. (%)
No. evaluated 334 331
Aspirin 299 (89.5) 307 (92.7) 0.17
Clopidogrel 170 (50.9) 168 (50.8) 1.00
Ticlopidine 1 (0.3) 1 (0.3) 1.00
Beta-blockers 281 (84.1) 279 (84.3) 1.00
Statins 308 (92.2) 306 (92.4) 1.00
ACE inhibitors 238 (71.3) 237 (71.6) 0.93
Duration of thienopyridine (clopidogrel or ticlopidine) 
treatment — mo
9.7±2.9 9.5±3.1 0.37
* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. ACE denotes angiotensin-
converting–enzyme.
† Differences in the numbers of patients who were evaluated with respect to quantitative coronary analysis and the suc-
cessful treatment of lesions are due to angiograms that could not be evaluated.
‡ Successful treatment of lesions was defined as the achievement of a final residual stenosis of less than 50% of the lu-
minal diameter and a coronary blood flow of grade 3, according to the TIMI classification, as assessed by the core labo-
ratory.
§ Differences in the numbers of patients who were evaluated are due to the deaths of patients before each follow-up and 
to missing data.
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ferences between the two treatment groups in-
fluenced the difference in outcome, multiple logis-
tic-regression analysis was performed, controlling 
for all variables that were found to be signifi-
cantly different at baseline. All statistical analy-
ses were performed with the use of SAS software, 
version 8.2 (SAS Institute), and all reported P val-
ues are two-sided.
Results
Study Patients
Between October 2003 and September 2004, 
2019 patients were screened and 715 were ran-
domly assigned to the two treatment groups (356 
to the sirolimus-stent group and 359 to the un-
coated-stent group) (Fig. 1). The most frequent 
reason for exclusion was fibrinolytic therapy for 
the index infarction. After randomization and 
treatment with the assigned stent, one patient in 
the sirolimus-stent group and two in the uncoat-
ed-stent group withdrew their consent to partici-
pate in the study.
Baseline Characteristics and Medications Used
Patients in the uncoated-stent group were slightly 
older and had a higher rate of previous PCI involv-
ing a nontarget coronary vessel, a lower rate of 
culprit lesions in the left anterior descending cor-
onary artery, and a higher rate of triple-vessel dis-
ease (Table 1). In both groups, the median time 
from the onset of chest pain to hospital admis-
sion was less than 4 hours, and the median inter-
val between arrival at the hospital and inflation 
of the balloon catheter was 60 minutes. The rate 
of use of glycoprotein IIb/IIIa–receptor inhibitors 
and the specific agents used did not vary signifi-
cantly between the two groups (Table 2).
Clinical Outcome at 1 Year
The primary end point of the study — target-ves-
sel failure at 1 year — occurred in 7.3% of patients 
in the sirolimus-stent group and in 14.3% in the 
uncoated-stent group (P = 0.004) (Table 3). This 
difference was due almost entirely to significant 
differences in the rates of target-vessel revascu-
larization. There was no significant difference 
between the sirolimus-stent group and the uncoat-
ed-stent group in the rates of death (2.3% and 
2.2%, respectively; P = 1.00), recurrent myocardi-
al infarction (1.1% and 1.4%, respectively; P = 1.00), 
or in-stent thrombosis (3.4% and 3.6%, respec-
tively;  P = 1.00). The actuarial rate of survival free 
from target-vessel failure was significantly higher 
in the sirolimus-stent group than in the uncoat-
ed-stent group (92.5% vs. 85.2%, P<0.001) (Fig. 2).
Table 3. Clinical Events at 1 Year.*
Event
Sirolimus-Eluting 
Stent
(N = 355)
Uncoated
Stent
(N = 357) P Value
number (percent)
Target-vessel failure 26 (7.3) 51 (14.3) 0.004
Clinically driven target-vessel revascularization 20 (5.6) 48 (13.4) <0.001
PCI 20 (5.6) 47 (13.2) <0.001
CABG 0 2 (0.6) 0.50
Death 8 (2.3) 8 (2.2) 1.00
Cardiac causes 7 (2.0) 5 (1.4) 0.58
Noncardiac causes 1 (0.3) 3 (0.8) 0.62
Recurrent myocardial infarction 4 (1.1) 5 (1.4) 1.00
Stent thrombosis 12 (3.4) 13 (3.6) 1.00
Acute 2 (0.6) 3 (0.8) 1.00
Subacute 9 (2.5) 8 (2.2) 0.81
Late 1 (0.3) 2 (0.6) 1.00
Angiographically proven stent thrombosis 7 (2.0) 12 (3.4) 0.35
* CABG denotes coronary-artery bypass grafting.
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Multivariate analysis of the primary end point 
was performed to control for all significant vari-
ables in Tables 1 and 2, including the use of clo-
pidogrel, at 6 months. On the basis of this adjusted 
analysis, patients in the sirolimus-stent group 
were less than half as likely as those in the un-
coated-stent group to have target-vessel failure 
(odds ratio, 0.41; P = 0.001).
Angiographic Follow-up Study
Of the 210 patients included in the angiographic 
substudy, 174 underwent angiography at 8 months 
(82.8%) and 170 had qualifying angiograms 
(81.0%) (Fig. 1 and Table 4). Patients in the angio-
graphic study, as compared with those not in the 
study, tended to have higher rates of target-vessel 
failure (13.3% vs. 9.8%, P = 0.19) and revascular-
ization (12.4% vs. 8.4%, P = 0.12), although these 
differences were not significant. However, the re-
duction in target-vessel failure in the sirolimus-
stent groups was similar whether or not follow-
up angiography was performed. At 8 months, 
sirolimus-eluting stents, as compared with un-
coated stents, were associated with significant 
mean reductions in in-stent late luminal loss 
(0.14±0.49 mm vs. 0.83±0.52 mm, P<0.001) and 
in-stent restenosis (3.5% vs. 20.3%, P = 0.001).
Discussion
In our trial, the use of sirolimus-eluting stents 
during primary PCI was associated with a reduc-
tion in the incidence of target-vessel failure at 
1 year, as compared with the use of uncoated 
stents (7.3% vs. 14.3%, P = 0.004). This difference 
was mainly driven by a reduction in the incidence 
of target-vessel revascularization. The results of 
the angiographic follow-up study suggest that the 
mechanism of benefit involves the suppression 
of neointimal proliferation among patients receiv-
ing sirolimus-eluting stents. The average in-stent 
late luminal loss in the sirolimus-stent group in 
our study was similar to that in previous studies 
of patients undergoing elective procedures.2,3,10
Rates of stent thrombosis were similar in the 
sirolimus-stent and uncoated-stent groups (3.4% 
and 3.6%, respectively; P = 1.00). These rates were 
higher than those in previous studies. Reported 
rates of stent thrombosis vary according to the 
clinical presentation and the definition used. In 
recent trials of sirolimus-eluting stents that in-
cluded only elective cases and used the same defi-
nition that we used in our trial, cumulative rates 
of stent thrombosis ranged from 0 to 1.1%.1-3,10 
A higher rate (2.0%) was reported for sirolimus-
eluting stents in the Sirolimus-Eluting Stent Com-
pared with Paclitaxel-Eluting Stent for Coronary 
Revascularization (SIRTAX) trial (a comparison of 
the Cypher stent and the Taxus stent), which in-
cluded both patients with and those without acute 
myocardial infarction.11 Elsewhere in this issue of 
the Journal, Laarman et al.12 report the results of 
the Paclitaxel-Eluting Stent versus Convention-
al Stent in Myocardial Infarction with ST-Segment 
Elevation (PASSION) trial, which showed a lower 
overall rate of stent thrombosis (1%) than did our 
study. However, angiographic proof was required 
for the diagnosis of stent thrombosis, and ad-
judication was not performed by an independent 
clinical events committee. The rates of stent 
thrombosis in the STRATEGY trial were 0% in the 
group receiving sirolimus-eluting stents and 3% in 
the group receiving uncoated stents.6 The 1-month 
rate of stent thrombosis in trials and registries 
with uncoated stents in acute myocardial infarc-
tion ranges from 0.9 to 4.3%.9,13-19
Procedural factors may have contributed to 
in-stent thrombosis in our study. Suboptimal pro-
cedural regimens of aspirin and heparin were al-
lowed, with minimal aspirin doses of 100 mg and 
a minimal activated clotting time of 250 seconds, 
in contrast to recent recommendations.20 Further-
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Figure 2. Actuarial Rate of Survival Free from Target-Vessel Failure 
among Patients Who Received Either a Sirolimus-Eluting Stent or an 
Uncoated Stent.
The rate of event-free survival was significantly higher in the group receiv-
ing a sirolimus-eluting stent than in the uncoated-stent group (P<0.001 
by the log-rank test).
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more, incomplete stent deployment favoring in-
stent thrombosis cannot be ruled out, since the 
mean residual stenosis after the procedure was 
higher in both groups than that in previous stud-
ies.1,2 Finally, our definition of acute and sub-
acute thrombosis was broad and included both 
death and repeated myocardial infarction if angio-
graphic proof of stent patency was not available. 
In contrast, the definition of late thrombosis re-
quired angiographic proof of stent thrombosis. 
Table 4. Angiographic Measurements Obtained at the Time of the Index Procedure and at Follow-up at 8 Months.*
Variable No. of Patients† Sirolimus-Eluting Stent Uncoated Stent P Value
Patients studied — no.
Initial angiographic subgroup 210 104 106
Follow-up angiography completed 174 90 84
Follow-up angiography qualifying for analysis 170 87 83
Before procedure
Diameter of reference vessel — mm 79 2.75±0.48 2.80±0.59 0.67
Minimal luminal diameter — mm 203 0.16±0.29 0.20±0.35 0.49
Stenosis — % of luminal diameter 203 94.6±11.1 93.30±13.0 0.45
Immediately after procedure
Diameter of reference vessel — mm 200 2.92±0.46 2.93±0.50 0.95
Minimal luminal diameter — mm
In stent 200 2.52±0.41 2.57±0.44 0.44
In lesion 200 2.30±0.48 2.30±0.54 0.92
Stenosis — % of luminal diameter
In stent 207 13.4±6.4 11.4±9.1 0.08
In lesion 207 18.6±8.1 19.4±9.1 0.50
Acute gain — mm
In stent 195 2.36±0.50 2.38±0.54 0.84
In lesion 195 2.14±0.52 2.11±0.6 0.70
Follow-up at 8 mo
Diameter of reference vessel — mm 144 2.85±0.54 2.79±0.56 0.54
Minimal luminal diameter — mm
In stent 144 2.42±0.59 1.78±0.61 <0.001
In lesion 144 2.14±0.61 1.76±0.61 <0.001
Stenosis of luminal diameter — %
In stent 159 16.4±13.2 37.1±16.1 <0.001
In lesion 159 24.6±13.8 37.9±16.5 <0.001
Late luminal loss — mm
In stent 138 0.14±0.49 0.83±0.52 <0.001
In lesion 138 0.17±0.47 0.56±0.60 <0.001
Proximal edge 131 0.21±0.47 0.29±0.51 0.38
Distal edge 137 0.03±0.35 0.09±0.50 0.46
Binary restenosis — no. (%)‡
In stent 159 3 (3.5) 15 (20.3) 0.001
In lesion 159 6 (7.1) 15 (20.3) 0.02
Proximal edge 153 3 (3.5) 3 (4.1) 1.00
Distal edge 158 0 1 (1.4) 0.47
* Plus–minus values are means ±SD.
† The number listed for each angiographic variable is the number of angiograms that could be evaluated for the study patients.
‡ The percentages in this category are the number of patients divided by the number of angiograms that could be evaluated. 
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Accordingly, 30-day rates of stent thrombosis may 
have been overestimated and those of late throm-
bosis underestimated.
In comparison with our study, trials and reg-
istries of primary PCI in patients with acute myo-
cardial infarction with ST-segment elevation have 
reported lower rates of repeated revasculariza-
tion. In fact, our rates are similar to those of previ-
ous studies in patients in stable condition.9,13-18 
This finding may be related to the effect of angio-
graphic follow-up in a subgroup of patients, since 
revascularization rates tended to be higher among 
patients undergoing follow-up angiography. Nev-
ertheless, the significant difference in the rates 
of target-vessel failure was maintained in the sub-
group of patients without angiographic follow-up. 
Furthermore, noninvasive testing was performed 
on a routine basis at 6 months, an approach that 
may have led to an increased rate of ischemia-
driven revascularization. Another factor may have 
been the speed of intervention (median interval 
from arrival at the hospital to inflation of the bal-
loon catheter, 60 minutes), which left patients 
with a relatively large amount of viable myocar-
dium at risk. In the PASSION trial, the revascu-
larization rate in the group receiving uncoated 
stents was surprisingly low, and the incidence of 
the primary end point was lower than the ex-
pected rate. The enrollment of fewer patients with 
diabetes and more patients with larger target ves-
sels in the PASSION trial may account for these 
differences.12
Our results cannot be generalized to all pa-
tients with acute myocardial infarction, since 
high-risk patients were excluded. Furthermore, our 
findings cannot be extended to other drug-elut-
ing stents. Despite adjudication of events by an 
independent clinical events committee, the single-
blind study design is an obvious limitation. This 
is especially true since the beneficial effect of 
sirolimus-eluting stents on the primary end point 
was almost entirely due to a reduction in target-
vessel revascularization, which was performed by 
investigators who were not specifically blinded 
to the study assignment of each patient. Although 
an analysis that was adjusted for differences be-
tween treatment groups in baseline characteristics 
did not change the findings, other variables might 
have influenced them. Finally, an assessment of 
long-term safety and durability will require longer 
follow-up of a larger cohort of patients.
In summary, in our study, patients with acute 
myocardial infarction with ST-segment elevation 
who received sirolimus-eluting stents had a sig-
nificantly lower rate of target-vessel failure than 
those who received uncoated stents. This differ-
ence was due almost entirely to a significant re-
duction in the rate of target-vessel revasculariza-
tion. An angiographic follow-up study showed 
significant reductions in in-stent restenosis and 
in-stent late luminal loss.
Supported by Cordis, Johnson & Johnson.
Drs. Spaulding, Henry, Teiger, Beatt, Carrié, Slama, Varenne, 
and Bode report having received consulting or lecture fees from 
Cordis, Johnson & Johnson; and Dr. Beatt, grant support from 
Cordis, Johnson & Johnson. Drs. Cebrian, Stoll, and Snead are full-
time employees of Cordis, Johnson & Johnson, and Drs. Stoll 
and Snead report holding equity interest in the company. No 
other potential conflict of interest relevant to this article was 
reported.
We are indebted to the patients who agreed to participate in 
the study; to the study coordinators, technicians, and nurses in 
the participating centers; and to Rita Dalal and Lorraine Wheel-
er for their editorial assistance.
appendix
The following investigators and institutions participated in the TYPHOON study: Steering Committee: C. Spaulding, C. Bode, E. 
Bramucci, P. Henry, E. Teiger, D. Carrie, M. Slama, K. Beatt; Sponsor: Cordis, Warren, NJ — D. Donohoe (medical director), D. Snead, 
R. Dalal, S. Sun; Cordis, Waterloo, Belgium — H.-P. Stoll (program director), A. Cebrian (program coordination), L. Wheeler; Data and 
Safety Monitoring Board: B. Meier, Switzerland; B. Lancelin, France; J.-F. Neumann, Germany; Clinical Events Committee: A. Caspi 
(chair), Israel; G. Maurer, Austria; S. Cook, Switzerland; Data Management and Monitoring: Hesperion, Clinical Development Services, Allschwil, 
Switzerland — V. Charlon (director); C. Berge; P. Rush; Electronic Data Capture: PPD GlobalView Web Services, New Hope, MN; Core Angio-
graphic Laboratory: Bio Imaging Technologies, Leiden, the Netherlands — A. Van Weert (director); Clinical Sites: Royal Perth Hospital, Perth, Aus-
tralia — R. Clugston, M. Bonner; Hôpital Cantonal de Genève, Geneva — E. Camenzind, N. Masson; Nemocnice Ceske, Budejovice, Czech Republic 
— L. Pesl; Poruba School of Medicine, Poruba, Czech Republic — R. Stipal, L. Pleva; Medizinische Universitätsklinik Freiburg, Freiburg, Germany — C. 
Bode, M. Zehender, S. Richter; Universitätskliniken des Saarlandes, Homburg Saar, Germany — G. Nickenig, N. Werner; Medizinische Klinik und 
Poliklinik Johannes-Gutenberg-Universität, Mainz, Germany — F. Post; Københavns Amtssygehus Gentofte, Hellerup, Denmark — U. Abildgaard, A. 
Galloe; Virgen de la Arrixaca, Murcia, Spain — M. Valdés, E. Pinar; Hôpital Européen Georges Pompidou, Paris — N. Danchin; Institut Mutualiste 
Montsouris, Paris — A. Dibie, F. Larrazet, F. Philippe; Clinique du Millénaire, Montpellier, France — X. De Boisgelin, G. Levy; Hôpital Lariboisiere, 
Paris — P. Henry, G. Sideris, R. Fressonnet; Hôpital Bichat, Paris — J.-M. Juliard, P. Aubry; Hôpital Tenon, Paris — P. Michel, E. Garbarz; 
Hôpital Béclère, Clamart, France — M. Slama, P. Colin; Hôpital Cochin, Paris — C. Spaulding, O. Varenne; Henri Mondor Hospital, Paris — E. 
Teiger, J. Dubois-Randé, S. Champagne; Centre Hospitalier Universitaire Toulouse–Hôpital Rangueil, Toulouse, France — D. Carrié, J. Roncalli, J. 
Cahuzac; Clinique Les Fleurs, Marseille, France — P. Commeau, P. Barragan; Hôpital Guillaume et René Laennec, Centre Hospitalier Universitaire Nord, 
St. Herblain, France — P. Guerin, A. Tirouvanziam; Clinique St. Augustin, Bordeaux, France — O. Darremont, J. Leymarie; Centre Hospitalier Ré-
Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org on September 15, 2009 . For personal use only. No other uses without permission. 
n engl j med 355;11 www.nejm.org september 14, 20061104
sirolimus-eluting stents in acute myocardial infarction
gional d’Orleans–Hôpital de la Source, Orleans, France — O. Dibon; Clinique Pasteur, Toulouse, France — J. Fajadet, B. Farah, B. Assoun; Centre 
Cardiologique du Nord, Saint Denis, France — P. Guyon, B. Chevalier; Clinique Victor Pauchet, Amiens, France — A. Py, E. Dadez; Centre Hospitalier 
Universitaire de Rennes, Rennes, France — H. Le Breton, M. Bedossa; Centre Hospitalier Universitaire Mulhouse, Mulhouse, France — L. Jacquemin, 
R. ElBelghit; Institut Hospitalier Jacques Cartier, Massy, France — M. Morice, T. Lefèvre; Centre Hospitalier Universitaire Avignon, Avignon, France 
— M. Pansieri, M. Metge; Clinique de la Casamance, Aubagne, France — B. Valeix; Clinique Médico-Chirurgicale Les Fontaines, Melun, France — P. 
Dupouy, E. Aptecar; Cardiovascular Center, Semmelweis University, Budapest, Hungary — B. Merkely, G. Szabó; Wolfson Medical Center, Holon, Is-
rael — Y. Rozenman, V. Witzling; Assaf Harofeh Medical Center, Zrifin, Israel — R. Krakover, I. Zyssman; Soroka Medical Center, Beer Sheva, Israel 
— R. Ilia, C. Cafri; Souraski Medical Center, Tel Aviv, Israel — H. Miller, A. Finkelstein; Istituto di Ricovero e Cura a Carattere Scientifico Policlinico 
San Matteo, Pavia, Italy — E. Bramucci, M. Ferlini, U. Canosi; San Filippo Neri Hospital, Rome — G. Richichi, V. Pasceri; Azienda Ospedale Luigi 
Sacco, Milan — P. Viecca; Azienda Ospedaliera Careggi, Florence, Italy — M. Margheri, C. Giglioli; Pauls Stradins University Hospital, Riga, Latvia 
— A. Erglis; I. Narbute; University Medical Center Utrecht, Utrecht, the Netherlands — P. Stella; P. Elsman; Slaskie Centrum Chorób Serca, Zabrze, 
Poland — L. Poloński; Hospital Fernando Fonseca, Amadora, Portugal — P. Farto e Abreu; Hospital Garcia Orta, Almada, Portugal — H. Pereira; 
Hammersmith Hospital, London — K. Beatt; and Southampton General Hospital, Southampton, United Kingdom — K. Dawkins.
references
Morice M-C, Serruys PW, Sousa JE, et 
al. A randomized comparison of a siroli-
mus-eluting stent with a standard stent 
for coronary revascularization. N Engl 
J Med 2002;346:1773-80.
Moses JW, Leon MB, Popma JJ, et al. 
Sirolimus-eluting stents versus standard 
stents in patients with stenosis in a native 
coronary artery. N Engl J Med 2003;349:
1315-23.
Schofer J, Schluter M, Gershlick AH, 
et al. Sirolimus-eluting stents for treatment 
of patients with long atherosclerotic lesions 
in small coronary arteries: double-blind, 
randomized controlled trial (E-SIRIUS). 
Lancet 2003;362:1093-9.
Saia F, Lemos PA, Lee CH, et al. Siroli-
mus-eluting stent implantation in ST-eleva-
tion acute myocardial infarction: a clini-
cal and angiographic study. Circulation 
2003;108:1927-9.
Lemos PA, Lee CH, Degertekin M, et 
al. Early outcome after sirolimus-eluting 
stent implantation in patients with acute 
coronary syndromes: insights from the 
Rapamycin-Eluting Stent Evaluated At Rot-
terdam Cardiology Hospital (RESEARCH) 
registry. J Am Coll Cardiol 2003;41:2093-
9.
Valgimigli M, Percoco G, Malagutti P, 
et al. Tirofiban and sirolimus-eluting stent 
vs abciximab and bare-metal stent for acute 
myocardial infarction: a randomized tri-
al. JAMA 2005;293:2109-17.
Serruys PW, Foley DP, de Feyter PJ, eds. 
Quantitative coronary angiography in clini-
cal practice. Dordrecht, the Netherlands: 
Kluwer Academic, 1994.
The TIMI Study Group. The Thrombol-
ysis in Myocardial Infarction (TIMI) trial: 
1.
2.
3.
4.
5.
6.
7.
8.
phase I findings. N Engl J Med 1985;312:
932-6.
Grines CL, Cox DA, Stone GW, et al. 
Coronary angioplasty with or without 
stent implantation for acute myocardial 
infarction. N Engl J Med 1999;341:1949-56.
Morice MC, Colombo A, Meier B, et al. 
Sirolimus- vs paclitaxel-eluting stents in de 
novo coronary artery lesions: the REALITY 
trial: a randomized controlled trial. JAMA 
2006;295:895-904.
Windecker S, Remondino A, Eberli FR, 
et al. Sirolimus-eluting and paclitaxel-
euting stents for coronary revasculariza-
tion. N Engl J Med 2005;353:653-62.
Laarman GJ, Suttorp MJ, Dirksen MT, 
et al. Paclitaxel-eluting versus uncoated 
stents in primary percutaneous coronary 
intervention. N Engl J Med 2006;355:1105-
13.
Spaulding C, Cador R, Benhamda K, 
et al. One-week and six-month angio-
graphic controls of stent implantation 
after occlusive and nonocclusive dissec-
tion during primary balloon angioplasty 
for acute myocardial infarction. Am J Car-
diol 1997;79:1592-5.
Stone GW, Grines CL, Cox DA, et al. 
Comparison of angioplasty with stenting, 
with or without abciximab, in acute myo-
cardial infarction. N Engl J Med 2002;346:
957-66.
Maillard L, Hamon M, Khalife K, et al. 
A comparison of systematic stenting and 
conventional balloon angioplasty during 
primary percutaneous transluminal coro-
nary angioplasty for acute myocardial in-
farction. J Am Coll Cardiol 2000;35:1729-
36.
Antoniucci D, Santoro GM, Bolog-
9.
10.
11.
12.
13.
14.
15.
16.
nese L, Valenti R, Trapani M, Fazzini PF. 
A clinical trial comparing primary stent-
ing of the infarct-related artery with opti-
mal primary angioplasty for acute myocar-
dial infarction: results from the Florence 
Randomized Elective Stenting in Acute 
Coronary Occlusions (FRESCO) trial. J Am 
Coll Cardiol 1998;31:1234-9.
Rodriguez A, Bernardi V, Fernandez M, 
et al. In-hospital and late results of coro-
nary stents versus conventional balloon 
angioplasty in acute myocardial infarc-
tion (GRAMI trial). Am J Cardiol 1998;81:
1286-91.
Saito S, Hosokawa G, Tanaka S, Naka-
mura S. Primary stent implantation is 
superior to balloon angioplasty in acute 
myocardial infarction: final results of the 
primary angioplasty versus stent implan-
tation in acute myocardial infarction 
(PASTA) trial. Catheter Cardiovasc Interv 
1999;48:262-8.
Monassier JP, Hamon M, Elias J, et al. 
Early versus late coronary stenting follow-
ing acute myocardial infarction: results of 
the STENTIM I Study (French Registry of 
Stenting in Acute Myocardial Infarction). 
Cathet Cardiovasc Diagn 1997;42:243-8.
Smith SC Jr, Feldman TE, Hirshfeld JW 
Jr, et al. ACC/AHA/SCAI 2005 guideline up-
date for percutaneous coronary interven-
tion: a report of the American College of 
Cardiology/American Heart Association 
Task Force on Practice Guidelines (ACC/
AHA/SCAI Writing Committee to Update 
the 2001 Guidelines for Percutaneous Coro-
nary Intervention). (Available at http://www.
acc.org/clinical/guidelines/percutaneous/
update/index.pdf.)
Copyright © 2006 Massachusetts Medical Society.
17.
18.
19.
20.
Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org on September 15, 2009 . For personal use only. No other uses without permission. 
